ZZ Biotech is a technology company.
ZZ Biotech has raised $1.0M across 1 funding round.
ZZ Biotech has raised $1.0M in total across 1 funding round.
ZZ Biotech is a clinical-stage biopharmaceutical company developing innovative biologic treatments, primarily 3K3A-APC, a genetically engineered variant of human activated protein C optimized for therapeutic use.[1][2] It targets ischemic stroke, neurodegenerative diseases, neurological conditions, and chronic wound healing, addressing major unmet medical needs in these areas.[1][3] The company, based in Houston, Texas (with some references to Las Vegas, Nevada), is at the Series A stage and remains active, with its Mosaic Score recently improving by +20 points, signaling positive financial health and market potential.[1]
ZZ Biotech serves patients suffering from stroke-related brain damage, neurological disorders, and non-healing wounds, solving problems like limited effective treatments for ischemic stroke recovery and chronic wounds.[1][2][5] Its lead product shows promise in clinical development, with momentum from ongoing pipeline advancements and partnerships, such as handing off 3K3A-APC wound therapy development to Dermatherix.[5]
ZZ Biotech was formed in 2006 specifically to advance biologic treatments for ischemic stroke, marking its entry into clinical-stage development.[3][4] Key details on founders or initial partners are not specified in available sources, but the company emerged from research into innovative neuroprotectants, focusing on 3K3A-APC as a engineered variant designed for safer, more effective therapy compared to natural activated protein C.[2]
Early traction likely built around preclinical and clinical validation of 3K3A-APC for stroke, with pivotal expansion into neurodegenerative diseases and wound healing.[1] The company's evolution reflects a steady clinical progression, culminating in recent activities like supporting Dermatherix in advancing its drug for wound applications, demonstrating sustained momentum over nearly two decades.[5]
ZZ Biotech rides the wave of neuroprotective biologics and regenerative medicine, capitalizing on growing demand for stroke treatments amid an aging population and rising ischemic stroke incidence (a global pipeline of 55+ therapies).[1] Timing aligns with advances in protein engineering, enabling safer variants like 3K3A-APC to overcome limitations of traditional therapies, amid market drivers like unmet needs in acute stroke intervention and chronic wound care.[1][2]
Market forces favoring it include biotech funding for Series A clinical plays and interest in multi-indication biologics, influencing the ecosystem by contributing to stroke pipelines alongside players like Avilex Pharma and therapies such as Microlyse or Elezanumab.[1] Its work pushes boundaries in biologic safety and efficacy, potentially accelerating adoption in neurology and dermatology.
ZZ Biotech's next milestones likely involve clinical trial progress for 3K3A-APC in stroke and wounds, potentially through Dermatherix partnerships or further Series A funding to reach later-stage trials.[1][5] Trends like AI-driven drug design, personalized neurotherapeutics, and expanded wound healing markets (driven by diabetes prevalence) will shape its path, amplifying its role in addressing stroke's massive burden.
Its influence may evolve via licensing deals or acquisitions, solidifying impact in biologics—echoing its 2006 origins as a stroke innovator now expanding to heal both brain and body.[3][5]
ZZ Biotech has raised $1.0M in total across 1 funding round.
ZZ Biotech's investors include BioAdvance.
ZZ Biotech has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in March 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2014 | $1.0M Seed | BioAdvance |